Day: June 29, 2020
TORONTO, June 29, 2020 (GLOBE NEWSWIRE) — Rogers Communications Inc. plans to release its second quarter 2020 financial results on Wednesday, July 22, 2020, before North American financial markets open. The results will be distributed by newswire and posted at investors.rogers.com. Rogers’ management will host its quarterly teleconference with the investment community to discuss the results and outlook at 8:00 a.m. ET.To access the teleconference, the live webcast will be available on the Investor Relations section of Rogers’ website at investors.rogers.com. Alternatively, the teleconference can be accessed by dialing 416-915-3239 (1-800-319-4610 toll free for North America) at least ten minutes prior to the scheduled start time and requesting access to Rogers’ second quarter 2020 results teleconference.An archive of the presentation...
Cellectis S.A. Reports Results from Annual Shareholders’ General Meeting Held on June 29, 2020
Written by Customer Service on . Posted in Public Companies.
NEW YORK, June 29, 2020 (GLOBE NEWSWIRE) — Cellectis S.A. held its Annual Shareholders’ General Meeting (Euronext Growth: ALCLS – Nasdaq: CLLS) on June 29, 2020 at its head office in Paris, France.At the meeting, during which more than 63% of voting rights were exercised, Resolutions 1 through 22, and Resolutions 26 through 28 were adopted. Resolutions 23, 24, 25 and 29 were rejected. The detailed results of the vote and the resolutions are available on the company’s website: https://www.cellectis.com/en/investors/general-meetings/About CellectisCellectis is developing the first of its kind allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients. As a clinical-stage biopharmaceutical company with over 20 years of expertise...
Predictive Oncology Inc. Announces Receipt of Cash Proceeds of $2.2 Million from Exercise of Warrants
Written by Customer Service on . Posted in Public Companies.
MINNEAPOLIS, June 29, 2020 (GLOBE NEWSWIRE) — Predictive Oncology Inc. (the “Company,” “Predictive Oncology,” “we,” “our” or “us”) (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced the closing of its previously announced transaction resulting in gross cash proceeds to the Company of approximately $2.2 million, prior to deducting placement agent fees and offering expenses, through the exercise of certain existing warrants by several holders to purchase an aggregate of up to 1,396,826 shares of common stock at an exercise price of $1.575 per share. The shares of common stock issued upon exercise of the existing warrants are registered for resale pursuant to a registration statement on Form S-1 (File No. 333-239207).In consideration...
HD Supply Holdings, Inc. Announces New Board Member and Conclusion of SEC Investigation
Written by Customer Service on . Posted in Public Companies.
ATLANTA, June 29, 2020 (GLOBE NEWSWIRE) — HD Supply Holdings, Inc. (NASDAQ: HDS), one of the largest industrial distributors in North America, today announced the appointment of Milford W. McGuirt to serve as a member of the Company’s Board of Directors. Mr. McGuirt was appointed on June 28, 2020, and will serve as a member of the Audit and Nominating and Corporate Governance Committees.“We are excited to welcome Milford to our board of directors. Milford brings a tremendous performance track record and decades of financial, operational and community leadership to the team,” said Joe DeAngelo, Chairman and CEO of HD Supply.Mr. McGuirt, served as managing partner of the Atlanta office and mid-south region of KPMG until his retirement. He additionally served as KPMG’s national audit sector leader and national industry leader...
Arvinas Appoints Wendy Dixon, Ph.D., to its Board of Directors
Written by Customer Service on . Posted in Public Companies.
NEW HAVEN, Conn., June 29, 2020 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Wendy Dixon, Ph.D., has joined its Board of Directors. Dr. Dixon is a well-respected leader with 40 years of broad and deep experience in the biopharmaceutical industry, including a strong track record of successful product launches.“We are pleased to welcome Wendy to Arvinas’ Board of Directors and look forward to her valuable insight related to key functions such as marketing, strategic planning, and business development,” said John Houston, Ph.D., President and Chief Executive Officer at Arvinas. “Wendy is joining Arvinas at a very exciting time as we continue to grow and accomplish milestones that bring us closer to our...
Condor Announces Director Election Results
Written by Customer Service on . Posted in Public Companies.
CALGARY, Alberta, June 29, 2020 (GLOBE NEWSWIRE) — Condor Petroleum Inc. (TSX: CPI), a Canadian based oil and gas company focused on exploration and production activities in Turkey and Kazakhstan, is pleased to announce that the following four director nominees were elected at the annual meeting of shareholders held on June 29, 2020:The TSX does not accept responsibility for the adequacy or accuracy of this news release.For further information, please contact Don Streu, President and CEO or Sandy Quilty, Vice President, Finance & CFO at 403-201-9694.
Labrador Technologies Inc. Announces Delay in Filing Quarterly Financial Statements
Written by Customer Service on . Posted in Public Companies.
Not for distribution to U.S. newswire services or for dissemination in the United States of America. Any failure to comply with this restriction may constitute a violation of U.S. securities law.CALGARY, Alberta, June 29, 2020 (GLOBE NEWSWIRE) — Labrador Technologies Inc. (TSXV: LTX) (“Labrador” or the “Company”) wishes to provide an update on COVID-19 matters and the status of the filing of interim financial statements, accompanying management discussion and analysis and related CEO and CFO certifications.The COVID-19 pandemic is creating unprecedented challenges to the economies, logistics and financial markets. The Company’s Board of Directors and Management are taking all necessary precautions to ensure the health of its employees and best manage the short-term challenges to the business.On May 20, 2020,...
Duke Realty Announces Results of Tender Offer for 3.875% Senior Notes Due 2022
Written by Customer Service on . Posted in Public Companies.
INDIANAPOLIS, June 29, 2020 (GLOBE NEWSWIRE) — Duke Realty Corporation (NYSE: DRE), a leading industrial property REIT, announced today the closing of the previously announced cash tender offer (the “Tender Offer”) by Duke Realty Limited Partnership (the “Operating Partnership”), its operating partnership, to purchase any and all of the outstanding 3.875% Senior Notes due 2022 (the “Notes”) issued by the Operating Partnership. The Tender Offer expired at 5:00 p.m., New York City time, on June 26, 2020 (the “Expiration Time”). The complete terms and conditions of the Tender Offer were set forth in an Offer to Purchase, dated June 22, 2020 (the “Offer to Purchase”), and the related Notice of Guaranteed Delivery.As of the Expiration Time, $216,260,000 aggregate principal amount of Notes had been validly tendered and not validly withdrawn....
Genmab Announces Very Favorable Topline Results from Phase 2 Clinical Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer
Written by Customer Service on . Posted in Public Companies.
Company AnnouncementGenmab and Seattle Genetics plan to discuss the results with the U.S. Food and Drug Administration (U.S. FDA)Full data to be presented at an upcoming medical meetingCopenhagen, Denmark; June 29, 2020 – Genmab A/S (Nasdaq: GMAB) today announced very favorable topline results from the Phase 2 single-arm clinical trial known as innovaTV 204 evaluating tisotumab vedotin administered every three weeks for the treatment of patients who have relapsed or progressed on or after prior treatment for recurrent or metastatic cervical cancer. Results from the trial showed a 24 percent confirmed objective response rate (ORR) by independent central review (95% Confidence Interval: 15.9% – 33.3%) with a median duration of response (DOR) of 8.3 months. The most common treatment-related adverse events (greater than or equal to...
XP Inc. Announces Preliminary Estimated 2Q20 Financial Results
Written by Customer Service on . Posted in Public Companies.
SÃO PAULO, Brazil, June 29, 2020 (GLOBE NEWSWIRE) — XP Inc. (Nasdaq: XP), a leading, technology-driven financial services platform and a trusted provider of low-fee financial products and services in Brazil, announced today the preliminary estimated financial results for the second quarter of 2020. The second quarter of 2020 has not ended yet and therefore our financial results for the three months ending June 30, 2020 are not yet finalized. The following information reflects our preliminary estimated results for this period:Gross Revenue (in R$ million)Gross revenue for the three months ending June 30, 2020 is expected to be between R$1,850 million and R$1,980 million, compared with R$1,236 million for the same period of 2019, representing a period over period expected growth of between 50% and 60%.Adjusted Net Margin ¹, ²Adjusted...